

STEM CELL AND REGENERATIVE MEDICINE

September 25-26, 2017 Berlin, Germany

Mesenchymal stem cells in the treatment for caesarean section skin scars

Zhengping Liu

Maternal & Child Health Hospital of Foshan - Southern Medical University, China

Cesarean delivery has already become a very common way of delivery around the world, especially in low-income countries. Hypertrophic scars and wound infections have affected younger mothers and frustrated obstetricians for a long time. Previous studies have demonstrated that MSCs are involved in enhancing diabetic wound healing. Therefore, this study is designed to investigate the safety and efficacy of using MSCs in the treatment for the caesarean section skin scars. This trial is a prospective, randomized, double-blind, placebo-controlled, single-center trial with three parallel groups. Eligible participants are randomly allocated to placebo, low-dose (3×10^6 cells transdermal hydrogel MSCs) or high-dose group (6×10^6 cells transdermal hydrogel MSCs), once a day for consecutive six days. Study duration is 6 months. The primary outcome of this trial is to evaluate the change of Vancouver scar scale during the 6 months. Adverse events, including severe and slight signs and symptoms, are documented in case report form. The study is conducted at the Department of Obstetric of Southern Medical University Affiliated Maternal & Child Health Hospital of Foshan. The first participant was recruited on September 14th, 2016. We hope to complete enrolment for the trial by September 2017 with all 6-month follow-up data expected by March 2018. This trial is the first investigation of the potential for therapeutic use of MSCs for the management of women's skin scar after cesarean delivery. The results will give us an effective therapeutic strategy to combat caesarean section skin scars, even in the uterine scar.

Biography

Zhengping Liu is an Obstetrician. He completed his MD from the Second Military Medical University in 1993. Currently, he is a Professor and Director of the Department of Obstetrics, Southern Medical University affiliated Maternal & Child Health Hospital of Foshan and the Deputy Director of the Foshan Institute of Fetal Medicine. His research interests include placenta previa and abnormally invasive placenta, fetal *in utero* treatment and regenerative medicine and stem cell clinical therapy. More than 30 articles reflect his research in reputed journals and has been serving as an Editorial Board Member of reputed. He is the pioneer of fetal surgery therapy *in utero* in China and has extensive collaborations with The Children's Hospital of Philadelphia. So far, he already performed dozens of clinical participants with stem cells during the past year.

Liuzphlk81@outlook.com

Notes: